Cancer

Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual…

2 months ago

Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach

BOSTON, Dec. 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with Carnegie-Mellon University (CMU) for an…

2 months ago

Toxin-to-Treasure: Chonnam National University Scientists Use Engineered Enzyme to Turn Formaldehyde Pollutant into High-Value Chemical

The study demonstrates engineered aldolase-catalyzed regioselective conversion of formaldehyde into L-glyceraldehyde JEOLLANAM-DO PROVINCE, South Korea, Dec. 22, 2025 /PRNewswire/ --…

2 months ago

datma and Rhythm Biosciences Announce Collaboration to Apply Federated Real-World Data to Genomic Diagnostic Development

The two companies will explore how datma's federated ecosystem can support Rhythm Biosciences' diagnostic development efforts as they shape a…

2 months ago

OsteoCentric Technologies Appoints Matthew Collier to Board of Directors

AUSTIN, Texas, Dec. 22, 2025 /PRNewswire/ -- OsteoCentric Technologies announced today the appointment of Matthew Collier to its Board of Directors,…

2 months ago

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular…

2 months ago

Ovation Science Sees Expanded Opportunities for Its Topical Products Following U.S. Cannabis Rescheduling

VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / December 22, 2025 / Ovation Science Inc. (CSE:OVAT)(OTC PINK:OVATF) ("Ovation"…

2 months ago

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist,…

2 months ago

Imviva Biotech Announces First Patient Dosed in Phase 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy

Patient achieved complete remission and well-tolerated safety profile, advancing path to Phase 2BOSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Imviva…

2 months ago

Vivos Inc Summarzes Preogress in its Animal Therapy Division

Kennewick, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The IsoPet division reported an 800% year-over-year increase…

2 months ago